Champions Oncology reported record fiscal 2026 oncology revenue of $59.4 million and fourth-quarter revenue of $13.8 million, while delivering adjusted EBITDA of $1.6 million for the full year and $0.16 million for the quarter. The company posted a fourth-quarter loss from operations of $0.522 million and a fiscal‑year loss from operations of $1.14 million, reflecting continued investment in radiopharmaceuticals, its data platform and commercial expansion. Cash totaled $4.9 million at April 30, 2026, with no debt on the balance sheet.

Financial Highlights

  • Revenue: Record total oncology revenue of $59.4 million for fiscal 2026; fourth-quarter revenue of $13.8 million.
  • Gross profit / margin proxy: Oncology services margin of 48% for the twelve months ended April 30, 2026, and 51% for the quarter ended April 30, 2026.
  • Operating income: Loss from operations of $1.14 million for fiscal year 2026 and loss from operations of $0.522 million for the fourth quarter.
  • Net income: Net loss of $1.175 million for fiscal 2026 and net loss of $0.667 million for the quarter ended April 30, 2026.
  • Adjusted results: Adjusted EBITDA of $1.585 million for fiscal 2026 and $158,000 for the fourth quarter; adjusted diluted EPS of $0.12 for the year and $0.01 for the quarter (Non-GAAP).

Business Highlights

  • Revenue growth drivers: Core research services strengthened and offset the absence of a prior-year non-recurring data license (~$4.5 million), producing a 4% year-over-year revenue increase.
  • Radiopharmaceuticals: Continued investment and a transition of certain radiopharmacology activities in‑house, temporarily raising outsourced costs during capability build-out.
  • Data platform and commercial expansion: Ongoing investments in the company’s data platform and expansion of the commercial organization to support both research services and data offerings.
  • Cost and operational discipline: Reduction in cost of oncology revenue for the quarter (down $462,000 year-over-year) driven by lower outsourced research services and lower compensation expense, contributing to improved operating leverage.
  • Working capital dynamics: Net cash used in operating activities for the quarter was approximately $2.2 million due primarily to timing of accounts receivable collections and a reduction in deferred revenue.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.